BioInvent International AB: Interim Report January-March 2024
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV)
"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs." - Martin Welschof, CEO of BioInvent.
EVENTS IN THE FIRST QUARTER
(R) CASI Pharmaceuticals reported positive interim Phase 1 data for BI-1206 in NHL in China
Supply agreement signed with AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence® (acalabrutinib)
BioInvent regained the rights to immuno-oncology targets from Exelixis
EVENTS AFTER THE END OF THE PERIOD
New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
(R)= Regulatory event
FINANCIAL INFORMATION First quarter 2024
Net sales, SEK 5.9 (16.2) million
Profit/loss after tax, SEK -77.9 (-73.7) million
Profit/loss after tax per share before and after dilution, SEK -1.18 (-1.12)
Cash flow from operating activities, SEK -65.9 (-78.9) million
Liquid funds, current and long-term investments at the end of the period, SEK 1,219.2 (1,546.4) million
About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact: Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0)46 286 85 50 Email: [email protected]
Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...
The Aesthetic Foundation, formerly known as the Aesthetic Surgery Education and Research Foundation (ASERF), proudly announces the election of Dr. Onelio Garcia Jr. "Oni", as its new President. Dr. Garcia's appointment heralds an exciting chapter for...
The Aesthetic Society proudly announces the appointment of Dr. Kiya Movassaghi, a board-certified plastic surgeon from Eugene, OR, as the President of The Aesthetic Society. Dr. Movassaghi's leadership will focus on strategically fortifying The...
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...